文章：

从实验室到临床：乳腺癌、肺癌及淋巴瘤治疗中心脏毒性的转化医学研究策略

From Bench to Bedside: Translational Approaches to Cardiotoxicity in Breast Cancer, Lung Cancer, and Lymphoma Therapies

原文发布日期：21 March 2025

DOI: 10.3390/cancers17071059

类型: Article

开放获取: 是

英文摘要：

Cardiotoxicity represents a critical challenge in cancer therapy, particularly in the treatment of thoracic tumors, such as lung cancer and lymphomas, as well as breast cancer. These malignancies stand out for their high prevalence and the widespread use of cardiotoxic treatments, such as chemotherapy, radiotherapy, and immunotherapy. This work underscores the importance of preclinical models in uncovering the mechanisms of cardiotoxicity and developing targeted prevention and mitigation strategies. In vitro models provide valuable insights into cellular processes, enabling the observation of changes in cell viability and function following exposure to various drugs or ionizing radiation. Complementarily, in vivo animal models offer a broader perspective, allowing for evaluating of both short- and long-term effects and a better understanding of chronic toxicity and cardiac diseases. By integrating these approaches, researchers can identify potential mechanisms of cardiotoxicity and devise effective prevention strategies. This analysis highlights the central role of preclinical models in advancing knowledge of cardiotoxic effects associated with common therapeutic regimens for thoracic and breast cancers.

摘要翻译： 

心脏毒性是癌症治疗中的一个关键挑战，尤其在肺癌、淋巴瘤等胸部肿瘤及乳腺癌的治疗中尤为突出。这些恶性肿瘤因其高发病率及化疗、放疗和免疫治疗等心脏毒性疗法的广泛应用而备受关注。本研究强调了临床前模型在揭示心脏毒性机制及制定针对性预防与缓解策略中的重要性。体外模型为细胞过程提供了宝贵见解，能够观察细胞在接触不同药物或电离辐射后的活力与功能变化。与之互补的是，体内动物模型提供了更广阔的视角，有助于评估短期与长期效应，并更好地理解慢性毒性及心脏疾病。通过整合这些方法，研究人员能够识别心脏毒性的潜在机制，并制定有效的预防策略。本分析凸显了临床前模型在深化对胸部肿瘤和乳腺癌常见治疗方案相关心脏毒性效应认知中的核心作用。

原文链接：

From Bench to Bedside: Translational Approaches to Cardiotoxicity in Breast Cancer, Lung Cancer, and Lymphoma Therapies